BofA Securities Reiterates Underperform Rating on BioXcel Therapeutics (BTAI), PT $4, 'still work to be done'
Tweet Send to a Friend
BofA Securities analyst Alec Stranahan reiterated an Underperform rating and $4.00 price target on BioXcel Therapeutics (NASDAQ: BTAI)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
